HR Execs on the Move

Tom Bigbee Healthcare Authority

www.bwwmh.com

 
Tom Bigbee Healthcare Authority is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Demopolis, AL. To find more information about Tom Bigbee Healthcare Authority, please visit www.bwwmh.com
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.bwwmh.com
  • 105 Us Highway 80 E
    Demopolis, AL USA 36732-3605
  • Phone: 334.289.4000

Executives

Name Title Contact Details

Similar Companies

Dietz Hwkins Internal Medicine

Dietz Hwkins Internal Medicine is a Sandy, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Elona Biotechnologies

Elona Biotechnologies , Inc. is a Greenwood, IN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

DGIMED Ortho

DGIMED Ortho is a Hopkins, MN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Assisted Living of Pasco Inc

Assisted Living of Pasco Inc is a New Port Richey, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Neurotrope Inc

Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage.  Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions.  These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization.  In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.